Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Astrazeneca Plc ADR (AZN)
Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 214,496,944
  • Shares Outstanding, K 3,099,667
  • Annual Sales, $ 44,351 M
  • Annual Income, $ 3,288 M
  • 60-Month Beta 0.51
  • Price/Sales 4.80
  • Price/Cash Flow 13.47
  • Price/Book 5.74
Trade AZN with:

Options Overview Details

View History
  • Implied Volatility 25.33% ( +25.33%)
  • Historical Volatility 18.48%
  • IV Percentile 38%
  • IV Rank 30.07%
  • IV High 38.30% on 10/11/22
  • IV Low 19.75% on 02/14/23
  • Put/Call Vol Ratio 0.45
  • Today's Volume 3,324
  • Volume Avg (30-Day) 3,983
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 166,385
  • Open Int (30-Day) 153,151

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate 0.84
  • Number of Estimates 4
  • High Estimate 0.85
  • Low Estimate 0.82
  • Prior Year 0.95
  • Growth Rate Est. (year over year) -11.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.77 +8.51%
on 03/08/23
69.26 -0.09%
on 03/27/23
+4.02 (+6.17%)
since 02/28/23
3-Month
62.51 +10.69%
on 02/02/23
72.12 -4.05%
on 01/10/23
+1.64 (+2.43%)
since 12/28/22
52-Week
52.65 +31.43%
on 09/26/22
72.12 -4.05%
on 01/10/23
+3.82 (+5.84%)
since 03/28/22

Most Recent Stories

More News
Astrazeneca (AZN) Gains But Lags Market: What You Should Know

In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day.

AZN : 69.20 (+0.82%)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.

SNY : 53.97 (-0.88%)
REGN : 811.50 (-0.96%)
AZN : 69.20 (+0.82%)
GSK : 35.27 (+0.60%)
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study

Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

AZN : 69.20 (+0.82%)
NVS : 91.58 (+1.54%)
BIIB : 275.13 (+0.41%)
IONS : 34.89 (-1.66%)
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints...

AZN : 69.20 (+0.82%)
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.

REGN : 811.50 (-0.96%)
SNY : 53.97 (-0.88%)
AZN : 69.20 (+0.82%)
GSK : 35.27 (+0.60%)
4 Best Pharma Stocks to Buy for the Long Haul

With the persistent rise in lifestyle diseases, the pharmaceutical industry is well poised for strong growth in the long term. Also, with the Fed likely to keep increasing the interest rates, the economy...

ABMD : 381.02 (+0.06%)
AZN : 69.20 (+0.82%)
BMY : 68.20 (+0.03%)
CINC : 29.06 (-0.48%)
JNJ : 153.43 (+0.08%)
NVS : 91.58 (+1.54%)
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.

AZN : 69.20 (+0.82%)
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

NEOG : 17.45 (-5.62%)
AZN : 69.20 (+0.82%)
3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030

These historically profitable dividend-paying stocks are ideal for risk-averse investors wanting to take advantage of a bear market discount.

COMP : 3.07 (+0.33%)
V : 222.36 (-0.42%)
YORW : 44.53 (+0.11%)
AZN : 69.20 (+0.82%)
3 Best Stocks to Buy Now for Long-Term Investors

Recent turmoil in the financial sector, renewed recession worries, and the Fed’s continued rate hikes paint an unfavorable picture for the stock market and economy. Amid this, long-term investors could...

ABEV : 2.87 (+0.35%)
AZN : 69.20 (+0.82%)
CS : 0.8708 (-0.74%)
CSCO : 51.43 (+0.51%)
FRC : 13.69 (-4.00%)
GS : 321.14 (+0.13%)
PNC : 127.03 (-1.47%)
SBNY : 0.1888 (-21.33%)
SIVB : 106.04 (-60.41%)
TMUS : 144.57 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 70.00
2nd Resistance Point 69.61
1st Resistance Point 69.41
Last Price 69.20
1st Support Level 68.81
2nd Support Level 68.42
3rd Support Level 68.22

See More

52-Week High 72.12
Last Price 69.20
Fibonacci 61.8% 64.68
Fibonacci 50% 62.39
Fibonacci 38.2% 60.09
52-Week Low 52.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar